Ohio State University Comprehensive Cancer Center, The Ohio State University, 300 W. 10th Avenue, Columbus, OH 43210, USA.
Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1745-55. doi: 10.1158/1055-9965.EPI-12-0016. Epub 2012 Aug 14.
Blood adipokines are associated with breast cancer risk; however, blood-breast adipokine correlations and factors that explain variation in adipokines are unknown.
Plasma (n = 155) and breast (n = 85) leptin and adiponectin were assessed by immunoassays in women with no history of cancer. Multivariable-adjusted regression models were used to determine breast adipokine associations.
Through body mass index (BMI)-adjusted analyses, we initially observed positive plasma-breast correlations for leptin (r = 0.41, P = 0.0002) and adiponectin (r = 0.23, P = 0.05). The positive plasma-breast correlation for leptin was strongest among normal weight women (r = 0.62), whereas the correlation for adiponectin was strongest among obese women (r = 0.31). In multivariable models, adjusting for BMI, demographic, reproductive, and lifestyle factors, plasma leptin was not associated with breast leptin, and only the highest quartile of plasma adiponectin was associated with tissue levels. Of the risk factors investigated, those that contributed most to the variation in breast tissue adipokines were BMI and race for leptin, oral contraceptive use and smoking status for adiponectin.
Although we report positive plasma-breast adipokine correlations overall, plasma adipokine concentrations may not be good surrogates for breast concentrations among all women. Predictors of breast adipokines vary, depending on subject characteristics, possibly explaining inconsistent epidemiologic results and they implicate differing pathways toward carcinogenesis.
A clearer understanding of the relationships between plasma adipokines and their levels within the target organ is necessary to better understand the impact of these hormones on breast cancer risk. Future studies are needed to identify additional factors associated with breast adipokines in target tissues.
血液脂肪因子与乳腺癌风险相关；然而，血液-乳房脂肪因子的相关性以及解释脂肪因子变化的因素尚不清楚。
通过免疫测定法评估了无癌症病史的女性的血浆（n=155）和乳房（n=85）中的瘦素和脂联素。采用多变量调整回归模型来确定乳房脂肪因子的相关性。
通过体重指数（BMI）调整分析，我们最初观察到血浆-乳房之间瘦素（r=0.41，P=0.0002）和脂联素（r=0.23，P=0.05）的正相关。瘦素的血浆-乳房正相关在正常体重女性中最强（r=0.62），而脂联素的相关性在肥胖女性中最强（r=0.31）。在多变量模型中，调整 BMI、人口统计学、生殖和生活方式因素后，血浆瘦素与乳房瘦素无关，只有血浆脂联素的最高四分位数与组织水平相关。在所研究的危险因素中，对乳房组织脂肪因子变化贡献最大的是 BMI 和种族（瘦素）、口服避孕药使用和吸烟状况（脂联素）。
尽管我们总体上报告了正的血浆-乳房脂肪因子相关性，但在所有女性中，血浆脂肪因子浓度可能不是乳房浓度的良好替代物。乳房脂肪因子的预测因素因受试者特征而异，这可能解释了不一致的流行病学结果，并暗示了不同的致癌途径。
需要更清楚地了解血浆脂肪因子与其在靶器官中水平之间的关系，以便更好地了解这些激素对乳腺癌风险的影响。需要进一步的研究来确定与靶组织中乳房脂肪因子相关的其他因素。
